Substance Abuse and Rehabilitation (Apr 2024)
Nalmefene Hydrochloride: Potential Implications for Treating Alcohol and Opioid Use Disorder
Abstract
MeShell Green,1 Charles A Veltri,1 Oliver Grundmann1,2 1College of Pharmacy, Department of Pharmaceutical Sciences, Midwestern University, Glendale, AZ, USA; 2College of Pharmacy, Department of Medicinal Chemistry, University of Florida, Gainesville, FL, USACorrespondence: Oliver Grundmann, Department of Medicinal Chemistry, College of Pharmacy, University of Florida, 1345 Center Drive, Room P3-20, Gainesville, FL, 32611, USA, Tel +1-352-246-4994, Fax +1-352-392-9455, Email [email protected]: Nalmefene hydrochloride was first discovered as an opioid antagonist derivative of naltrexone in 1975. It is among the most potent opioid antagonists currently on the market and is differentiated from naloxone and naltrexone by its partial agonist activity at the kappa-opioid receptor which may benefit in the treatment of alcohol use disorder. Oral nalmefene has been approved in the European Union for treatment of alcohol use disorder since 2013. As of 2023, nalmefene is available in the United States as an intranasal spray for reversal of opioid overdose but is not approved for alcohol or opioid use disorder as a maintenance treatment. The substantially longer half-life of nalmefene and 5-fold higher binding affinity to opioid receptors makes it a superior agent over naloxone in the reversal of high potency synthetic opioids like fentanyl and the emerging nitazenes. Nalmefene presents with a comparable side effect profile to other opioid antagonists and should be considered for further development as a maintenance treatment for opioid and other substance use disorders.Keywords: opioid antagonist, withdrawal, substance use disorder, kappa opioid receptor
